BioMAP Europe

Introducing Bio-Map Europe: the strategic market access plan ‘in a box’ for Biotech

If you are an innovative, SME Biotech company, in the clinic, with a potential approval in the next 3-4 years, but concerned about the evidence you will need to achieve successful pricing and reimbursement in the highly complex European markets, Bio-MAP Europe was designed specifically for you.

Bio-MAP Europe contains all the elements you will need from Value Strategy, Pricing, Clinical and HEOR Evidence to Value Communication, in one easy-to-use, comprehensive service package.

Bio-MAP Europe spans the development of Market Access strategy right through Value Story and economic model development, to pricing and reimbursement dossier preparation. We can even take care of individual country pricing and reimbursement dossier submission and Payer negotiation in Europe if you do not yet have the infrastructure in place.

Bio-MAP Europe is delivered by GalbraithWight, the leading global strategic Market Access Consultancy, with over 20 years’ Thought Leadership and successful experience delivering Market Access solutions for major global brands such as Yervoy, Opdivo, Keytruda, Ibrance, Eliquis and many more.

Our Biotech experience comes from working with a wide range of highly innovative Biotech companies on their pipeline assets, including Kite Pharma, Halozyme and Illumina.

Your project will be led by one of our team of highly experienced Consultants, each with an average of 20 years industry experience, which means they understand the pressures you are facing, and are focussed on delivering the right result for you and your new medicine. Our multi-disciplinary team of technical experts deliver each aspect of the Market Access workstreams, to the highest levels of quality and robustness. We work as an integral extension of your team, ensuring a seamless approach.

Commissioning our Bio-MAP Europe service means;

  1. your precious clinical trial investment works harder
  2. your innovation stands a much better chance of reaching those patients who need it most, through a clear, proven, systematic roadmap ensuring the right steps are taken at the right time, with the right deliverables, with the right quality
  3. your investors and shareholders may realize a higher level return on investment through a robust Market Access plan
  4. current and future investors’ confidence in eventual commercial success is increased

Call or email GalbraithWight today to discuss how Bio-MAP Europe can deliver the right Market Access plan and business outcomes for your innovative medicine.

Bio-MAP Europe Brochure

Post Navigation